The article full text is available here:
jnci.oxfordjournals.org/content/early/2014/03/07/jnci.dju007.full.pdf+htmlThe fact that the higher use of PSA testing has been associated with lower PCa mortality is not new but it has been ignored by those that continue to support the notion that there is limited value in testing with PSA for prostate cancer. Those folks have never fully explained the PCa mortality reduction experienced in the USA as compared to other countries in which the use of PSA is low or not available. In many of those countries there has not been a decline in mortality and in some countries there has been mortality increases.
Those treating PCa here need to avoid treating many men who could avoid the harms of treatment without the risk of cancer affecting them. This is something to consider here where the guidelines for testing with PSA, if followed as recommended, will result in an increase of deaths…
The authors concluded:
“In conclusion, in our population-based study we observed lower
incidence of metastatic prostate cancer, lower prostate cancer–specific mortality, and lower excess mortality in counties with high
vs low incidence of prostate cancer, reflecting PSA uptake. This
indicates that more-intense as compared with less-intense opportunistic PSA screening reduces prostate cancer mortality.”
Test, but be responsible by avoiding unnecessary treatment when possible!
RalphV